 |
 |

Fibrinolysin Studies in Hemophilia
JEROME I. BRODY, MD;
MOHAMED MOBARAK, MD;
PETER LAU, MD;
LAWRENCE H. BEIZER, MD
Arch Intern Med. 1966;118(3):241-244.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
THE PURPOSE of this investigation was to determine whether inappropriate fibrinolysis may be detected in the blood of patients with classical, sex-linked hemophilia (hemophilia A, factor VIII deficiency). The occurrence of spontaneous, unprovoked hemorrhage in many of these patients, without an actual change in the level of factor VIII,1 suggested that an accessory defect in coagulation, such as excess fibrinolysis, might play a role in causing unpredictable bleeding. Furthermore, the availability of -aminocaproic acid (EACA), an antifibrinolytic agent which has been used in the management of hemophilia,2,3 indicated the need to document a rational basis for this form of treatment.
Methods and Materials
A total of 26 patients, ranging in age from 3 to 19 years, participated in the study. Five families were represented by two brothers each, and one family by three children. The remaining 13 patients were unrelated. Certain clinical variables were deliberately incorporated into the
. . . [Full Text PDF of this Article]
Author Affiliations
PHILADELPHIA
From the Department of Medicine, the Graduate Hospital, and the University of Pennsylvania School of Medicine, Philadelphia.
Footnotes
Received for publication April 19, 1966; accepted June 7.
Reprint requests to the University of Pennsylvania, the Graduate Hospital, Philadelphia 191 (Dr. Brody).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|